Enable Medicine Raises $60M To Build The Search Engine For Biology - Enable Medicine
Summary
Menlo Park, CA - April 7, 2022 - Enable Medicine, a company that builds and integrates searchable maps of human disease, announces the closing of their Series A, raising $60M led by Anthos Capital and General Catalyst. With this round, the company is launching their spatial biology atlasing platform, empowering all biologists and clinicians to better understand how the organization of cells impact disease pathology, progression, and therapeutic response. Enable will use this fundraise to expand the product offerings it can provide to its research collaborators, including additional proteomic and transcriptomic assays, and increase the speed at which it generates searchable datasets and actionable insights from complex biological data.Enable Medicine provides researchers with the ability to build comprehensive maps of disease biology. The power of the BIOS is fully appreciated when scientists can easily search across hundreds of patients worth of spatial maps, surfacing clinically important cell types, interactions, and neighborhoods that previously could not be identified without the data organized and optimized for querying.To date, Enable Medicine has 50+ research collaborations ongoing on its platform, including work with labs at institutions including Harvards Dana-Farber Cancer Institute, Mayo Clinic, Parker Institute of Cancer Immunotherapy, Stanford University, UC San Francisco, and numerous others. Enable is a co-author on recent research publications and pre-prints including in Ulcerative Colitis, Pancreatic Ductal Adenocarcinoma, and Non-Small Cell Lung Cancer, with a number of additional manuscripts across a variety of diseases currently being drafted and in review.BIOS has also generated significant demand amongst biopharma companies, where clinicians and drug hunters use the platform to better understand patient segmentation strategies and mechanisms of action.The platform has begun to generate high-value therapeutic hypotheses, such as a greater understanding of certain cell types and interactions that could be driving non-response to therapies like Sanofis and Regenerons megablockbuster Dupixent, or Mercks flagship cancer immunotherapy drug, Keytruda.Enable is led by an interdisciplinary team of bioengineers, computational immunologists, and computer scientists and is supported by an advisory board of academic and industry leaders including Nobel Laureate Dr. Jim Allison and Dr. Padmanee Sharma (MD Anderson Cancer Center), Dr. Tom Bumol (Allen Institute of Immunology), Dr. Andrew Lo (MIT), Dr. James Zou (Stanford University), Dr. Christian Schuerch (University of Tubingen), Dr. Laurence Marton (AACR), and Dr. Paul Conley (10x Genomics, Twist Bioscience).